Singapore markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
43.76-0.40 (-0.91%)
At close: 04:03PM EDT
43.85 +0.09 (+0.21%)
Pre-market: 06:08AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close44.16
Open44.17
Bid43.66 x 3200
Ask43.92 x 2200
Day's range43.73 - 44.60
52-week range40.94 - 61.71
Volume22,962,293
Avg. volume17,660,841
Market cap245.596B
Beta (5Y monthly)0.65
PE ratio (TTM)8.51
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.60 (3.66%)
Ex-dividend date03 Nov 2022
1y target estN/A
  • Business Wire

    Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

    NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup

  • Business Wire

    Pfizer Declares Fourth-Quarter 2022 Dividend

    NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company’s common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, 2022. The fourth-quarter 2022 cash dividend will be the 336th consecutive quarterly dividend paid by Pfizer.

  • Business Wire

    Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries

    NEW YORK, September 22, 2022--Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of healt